Lampalizumab
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Geographic Atrophy
Conditions
Geographic Atrophy
Trial Timeline
Jul 21, 2016 → Jan 31, 2018
NCT ID
NCT02745119About Lampalizumab
Lampalizumab is a phase 3 stage product being developed by Roche for Geographic Atrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02745119. Target conditions include Geographic Atrophy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02745119 | Phase 3 | Terminated |
| NCT02247531 | Phase 3 | Terminated |
| NCT02247479 | Phase 3 | Terminated |
Competing Products
20 competing products in Geographic Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| avacincaptad pegol | Astellas Pharma | Phase 3 | 77 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2/3 | 65 |
| avacincaptad pegol | Astellas Pharma | Approved | 85 |
| Avacincaptad pegol (ACP) | Astellas Pharma | Pre-clinical | 23 |
| Avacincaptad Pegol + Sham | Astellas Pharma | Phase 3 | 77 |
| ABBV-6628 + SYFOVRE | AbbVie | Phase 1/2 | 41 |
| FWY003 + Placebo | Novartis | Phase 2 | 52 |
| CLG561 + LFG316 + Sham injection | Novartis | Phase 2 | 52 |
| LFG316 + Sham + LFG316 Lower dose | Novartis | Phase 2 | 52 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| RO7669330 + Syfovre™ + Izervay™ | Roche | Phase 1 | 33 |
| RO7303359 | Roche | Phase 1 | 33 |
| SAR446597 + Sham Comparator | Sanofi | Phase 1/2 | 40 |
| Pozelimab | Regeneron Pharmaceuticals | Phase 1 | 32 |
| IONIS-FB-Lrx + Placebo (sterline saline 0.9%) | Ionis Pharmaceuticals | Phase 2 | 49 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 74 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 18 |
| APL-2 + APL-2 | Apellis Pharmaceuticals | Phase 3 | 72 |
| APL-2, Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |